Tongue neoplasm

Summary

Tongue neoplasm (MONDO:0021240) is a cancer and 8 clinical trials. Top therapeutic interventions include sirolimus and luteolin. A subtype of tongue disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	tongue neoplasm
Mondo ID	MONDO:0021240
EFO	EFO:0003871
NCIT	C3416
SNOMED CT	126778001
UMLS	C0040411
MedGen	52778
Anatomy (UBERON)	UBERON:0001723
Is cancer (heuristic)	yes

Also known as: neoplasm of the tongue · neoplasm of tongue · tongue neoplasm (disease) · tongue tumor · tongue tumour · tumor of the tongue · tumor of tongue · tumour of the tongue · tumour of tongue

Disease family

This is a subtype of tongue disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › mouth disorder › tongue disorder › tongue neoplasm

Related subtypes (8): hypertrophy of tongue papillae, glossitis, hairy tongue, ankyloglossia, fissured tongue, isolated congenital hypoglossia/aglossia, digestive duplication cyst of the tongue, glossodynia

Subtypes (2): tongue cancer, benign neoplasm of tongue

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	5
PHASE1/PHASE2	1
PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01195922	PHASE1/PHASE2	COMPLETED	Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma
NCT02985255	PHASE2	UNKNOWN	Role of Neo-adjuvant Chemotherapy in Tongue Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue
NCT03288298	EARLY_PHASE1	UNKNOWN	Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line
NCT02584270	Not specified	RECRUITING	Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue
NCT06169605	Not specified	RECRUITING	Assessment of the Effect of Tumor Thickness and Site on Level IV Cervical Lymph Nodes in Squamous Cell Carcinoma of the Tongue and Floor of the Mouth: A Case Series Study
NCT03239834	Not specified	COMPLETED	Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making
NCT04041141	Not specified	WITHDRAWN	Oral Stent Device for Radiation Treatments of Oral Cancers
NCT06988449	Not specified	COMPLETED	Use of ST250 to Reconstruct Lateral Tongue Defects

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
SIROLIMUS	4	1
LUTEOLIN	2	1